Increased risk of recurrent venous thromboembolism during hormone replacement therapy: Results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET)

Thrombosis and Haemostasis

Volumn 84, Issue 6, 2000, Pages 961-967

  Hoibraaten E ^a   Qvigstad, E ^a   Arnesen, H ^a   Larsen, S ^a   Wickstrom E ^a   Sandset, P M ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Clinical trial; Estrogen; Hormone replacement therapy; Venous thromboembolism

Indexed keywords

ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTROGEN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HORMONE SUBSTITUTION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; POPULATION RESEARCH; POPULATION RISK; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 0034533428     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614156     Document Type: Article

References (37)

1. Perimenopausal hormone replacement therapy. Review of the literature
2. Estrogens in the prevention and treatment of postmenopausal osteoporosis: A review
3. The effect of postmenopausal estrogen therapy on bone density in elderly women
4. Treatment of postmenopausal osteoporosis with transdermal estrogen
5. Hormone therapy to prevent disease and prolong life in postmenopausal women
6. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer
7. Estrogen and coronary heart disease in women
8. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group
9. Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy. A report from the Boston collaborative drug surveillance program, Boston University Medical Center
10. Effects of long-term estrogen replacement therapy. I. Metabolic effects
11. Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems
12. Risk of vascular disease in women. Smoking, oral contraceptives, noncontraceptive estrogens, and other factors
13. Estrogen replacement therapy and the risk of venous thrombosis
14. Risk of venous thromboembolism in users of hormone replacement therapy
15. Prospective study of exogenous hormones and risk of pulmonary embolism in women
16. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens
17. Hormone replacement therapy and risk of venous thromboembolism: Population based case-control study
18. Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: A population-based study in southern Europe
19. Hormone replacement therapy with estradiol and risk of venous thromboembolism-a population-based case-control study
20. Assessment of the risk for venous thromboembolism among users of hormone replacement therapy
21. Reevaluation of the risk for venous thromboembolism with the use of oral contraceptives and hormone replacement therapy
22. Recent epidemiological studies of the association between hormone replacement therapy and venous thromboembolism. A review
23. Women with thrombophilia: Assessing the risks for thrombosis with oral contraceptives or hormone replacement therapy
24. HRT and the risk of deep vein thrombosis
25. The long-term clinical course of acute deep venous thrombosis
26. Risk factors for venous thrombosis: Prevalence, risk, and interaction
27. The effect of the duration of anticoagulation and other risk factors on the recurrence of venous thromboembolisms. Duration of anticoagulation study group
28. Venous thromboembolic disease and combined oral contraceptives: Results of international multicentre case-control study. World Health Organization collaborative study of cardiovascular disease and steroid hormone contraception
29. Optimal duration of oral anticoagulant therapy: A randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis
30. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer
31. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The duration of Anticoagulation Trial Study Group
32. The Leiden Thrombophilia Study (LETS)
33. High risk of thrombosis in patients homozygous for factor V leiden (activated protein C resistance)